Christopher French joined Canaccord Genuity through the acquisition of Petsky Prunier and is part of the firm’s healthcare investment banking practice. He has advised numerous HCIT, information, digital media and business services companies that support payers, providers, and life science companies. His practice has enjoyed strong recent success with fourteen completed transactions in the last thirty months. He also serves on the Board of Advisors of Crossix and USARx.
Prior to joining Petsky Prunier, Chris served as president and chief executive officer of Cadient Group, a private equity–backed digital agency for healthcare companies. Previously, he served in a number of leadership capacities — including senior vice president of global solutions marketing and corporate development — at Dendrite International, a publicly-traded provider of CRM software, information, and business services to the global life sciences industry. Prior to joining Dendrite, he was a corporate associate in the mergers and acquisitions practice at Skadden, Arps, Slate, Meagher & Flom, a leading global law firm.
Chris is a graduate of Fordham University School of Law and received a B.S. in economics from the Wharton School of the University of Pennsylvania.